Clene Inc. (CLNN): Nasdaq/NYSE listing notice — Clene receives Nasdaq extension to July 29, 2024 to cure $1 bid price deficiency; reverse split considered

Clene Inc.

Company failed to regain compliance by original Jan 29, 2024 deadline for minimum $1/share bid price.
Nasdaq granted additional 180-day period until July 29, 2024; shares continue trading on Nasdaq under CLNN.
Clene intends to cure deficiency, including via a reverse stock split if necessary.
If bid price does not close at $1.00+ for 10 consecutive business days by July 29, 2024, delisting may occur.
Company must also maintain market value of publicly held shares and other listing requirements.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Clene Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

January 30, 2024, the Company received a notice from Nasdaq that, while the Company has not regained compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), it is eligible for an additional 180 calendar day period, or until July 29, 2024, to regain compliance with the Minimum Bid Price Requirement (the “January Notice”). The January Notice has no immediate effect on the listing of the Company’s common stock and its common stock will continue to be listed on the Nasdaq Capital Market under the symbol “CLNN.” Nasdaq’s determination to grant an add

View on SEC.gov

Browse all listing & compliance notices →

Clene Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-002692

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.